Search results for " Polycystic Ovary Syndrome"

showing 7 items of 17 documents

Body composition of individuals with polycystic ovary syndrome

2009

Polycystic ovary syndrome (PCOS) is one of the principle forms of hyperandrogenism that affects women of reproductive age. Few studies have evaluated the body composition of patients with PCOS being based mainly on an evaluation of the quantity and distribution of the fat mass. Objectives: to evaluate the body composition of patients affected by PCOS and to establish the hormonal factors that determine possible differences in body composition compared with healthy women. Methods: 110 Caucasian women affected by clinical hyperandrogenism and/or irregular menstrual periods were included in the study; the control group was made up of 90 healthy Caucasian women, of reproductive age, without hyp…

HyperinsulinemiaSettore MED/18 - Chirurgia GeneraleMedicine (all)Body composition; Hyperinsulinemia; Polycystic ovary syndrome; Medicine (all)Body compositionPolycystic ovary syndrome
researchProduct

Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group

2011

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in females, with a high prevalence. The etiology of this heterogeneous condition remains obscure, and its phenotype expression varies. Two widely cited previous ESHRE/ASRMsponsored PCOS consensus workshops focused on diagnosis (published in 2004) and infertility management (published in 2008), respectively. The present third PCOS consensus report summarizes current knowledge and identifies knowledge gaps regarding various women's health aspects of PCOS. Relevant topics addressed-all dealt with in a systematic fashion-include adolescence, hirsutism and acne, contraception, menstrual cycle abnormalities, quality of life, e…

Infertilitymedicine.medical_specialtyConsensusMEDLINEmetabolic syndromeSettore MED/13 - EndocrinologiaPolycystic Ovary Syndrome Adolescence Metabolism Cardiovascular riskMetabolic DiseasesQuality of lifeSDG 3 - Good Health and Well-beingPregnancyRisk Factorscardiovascular diseaseNeoplasmsinsulin resistancemedicineHumanscancerPolycystic ovary syndromehirsutismhirsutismGynecologybiologypregnancy complicationsbusiness.industryPolycystic ovary syndrome (PCOS)cancer; cardiovascular disease; contraception; hirsutism; insulin resistance; metabolic syndrome; Polycystic ovary syndrome; pregnancy complications; quality of life; type 2 diabetesObstetrics and GynecologyAnti-Müllerian hormonemedicine.diseasePolycystic ovarycontraceptionquality of lifeReproductive MedicineCardiovascular DiseasesFamily medicinebiology.proteinEtiologyFemaletype 2 diabetesbusinessInfertility Female
researchProduct

Serum miRNAs in women affected by hyperandrogenic polycystic ovary syndrome: the potential role of miR-155 as a biomarker for monitoring the estropro…

2018

MicroRNAs can be used as very efficient circulating biomarkers. The role of microRNAs in polycystic ovary syndrome (PCOS) and the effects of antiandrogen therapy on microRNA expression is still not fully understood. A panel of serum microRNAs were retrotranscribed via looped reverse primer transcription specific for each miRNA and quantified via probe specific RT-PCR in 16 Caucasian hyperandrogenic PCOS women selected according to the Rotterdam criteria and in a subset of seven patients after four months of sequential reverse antiandrogenic therapy. All women recruited underwent an oral glucose tolerance test (OGTT) and a baseline total cholesterol, high density lipoproteins cholesterol, tr…

endocrine system diseasesEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismurologic and male genital diseasesSettore MED/13 - EndocrinologiamiR-155mir-15503 medical and health sciences0302 clinical medicineEndocrinologymicroRNAMedicineHumansAntiandrogen Therapy030219 obstetrics & reproductive medicineantiandrogenic therapy; biomarker; mir-155; Polycystic ovary syndrome; visceral adipose index; Endocrinology Diabetes and Metabolism; Endocrinology; Obstetrics and Gynecologybusiness.industryantiandrogenic therapyfungifood and beveragesObstetrics and GynecologyAndrogen Antagonistsvisceral adipose indexPolycystic ovaryCirculating biomarkersMicroRNAsCancer researchBiomarker (medicine)biomarkerFemalebusinesshormones hormone substitutes and hormone antagonistsBiomarkersPolycystic Ovary SyndromeGynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
researchProduct

Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society.

2012

Background Hirsutism, defined by the presence of excessive terminal hair in androgen-sensitive areas of the female body, is one of the most common disorders in women during reproductive age. Methods We conducted a systematic review and critical assessment of the available evidence pertaining to the epidemiology, pathophysiology, diagnosis and management of hirsutism. Results The prevalence of hirsutism is ~10% in most populations, with the important exception of Far-East Asian women who present hirsutism less frequently. Although usually caused by relatively benign functional conditions, with the polycystic ovary syndrome leading the list of the most frequent etiologies, hirsutism may be th…

hirsutism; androgen excess; guidelinesmedicine.medical_specialtyPediatricsHirsutismMEDLINETerminal hairAndrogen ExcessSettore MED/13 - EndocrinologiaIntervention (counseling)EpidemiologyMedicineHumansguidelineshirsutismSocieties MedicalHirsutism PCOS Hyperandrogenism Adrenal hyperplasia idiopathic hirsutismGynecologybusiness.industryObstetrics and Gynecologymedicine.diseaseSettore MED/40 - Ginecologia E OstetriciaPolycystic ovaryReproductive Medicinehirsutism androgen excess terminal hair polycystic ovary syndrome guidelinesEtiologyAndrogensFemaleandrogen excessbusinessHair FolliclePolycystic Ovary SyndromeHuman reproduction update
researchProduct

Comparison between different mathematical methods to calcolate insulin resistance in women with polycystic ovary syndrome (PCOS)

2003

mathematical methods insulin resistance polycystic ovary syndrome (PCOS)
researchProduct

Glucose transporter 4 mRNA expression in subcutaneous adipose tissue of women with PCOS remains unchanged despite metformin withdrawal: is there a ce…

2021

Purpose: Metformin induces GLUT-4 mRNA expression in insulin target tissues in PCOS. It is unclear how long this impact is sustained after withdrawal of metformin. We aimed to compare the effect of metformin withdrawal on GLUT-4 mRNA expression in subcutaneous adipose tissue after prior short (ST, 1 year, N = 11) and long term (LT, at least 3 years, N = 13) treatment in obese PCOS women. Methods: At baseline and 6 months after withdrawal, biopsy of subcutaneous adipose tissue followed by quantitative PCR analysis was performed to determine GLUT-4 mRNA expression. Results: We found no time/effect differences in GLUT-4 mRNA expression in ST (2-dCt at baseline 0.42 (0.16–0.48) vs 2-dCt after 6…

medicine.medical_specialtyendocrine system diseasesEndocrinology Diabetes and Metabolismmedicine.medical_treatmentMrna expressionGlucose Transport Proteins FacilitativeSubcutaneous FatAdipose tissueQuantitative PCR analysisEndocrinologyInternal medicineBiopsymedicineHumansRNA MessengerAdipose tissue GLUT-4 mRNA Metformin PCOS Adipose Tissue Female Humans RNA Messenger Subcutaneous Fat Metformin Polycystic Ovary Syndromemedicine.diagnostic_testbusiness.industryInsulinGlucose transporternutritional and metabolic diseasesMetforminMetforminEndocrinologyAdipose TissueFemaleSubcutaneous adipose tissuebusinessPolycystic Ovary Syndromemedicine.drug
researchProduct

Comparison of the effects of metformin and rosiglitazone in anovulatory women with polycystic ovary syndrome (PCOS)

2003

metformin rosiglitazone polycystic ovary syndrome (PCOS)
researchProduct